Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very.
Jon
As a recent MMI long/AAPL short, good to hear, although I took AAPL profits.
Jon (from IPad 1)
And I thought CTIC was finally flushing down to teens cents. But no, they put out a few PRs, buy some compound, and the stock doubles back to 40s (cents).
Jon
Is it you who I can thank for the turnaround down? <LOL>
Jon
GNVC
I got lucky - was asked by my dad's estate to clean up a biotech portfolio of three stocks worth low, low, low 6 figures which had only 3 names, none of which I really knew very well, and of what I did know, I only liked one, somewhat.
I got good advice from contacts (including rkrw - thanks rkrw) and began to slowly ease the stocks out as they were all running (this was late 2009). I began to think I was an idiot because I had sold half of each of the main two components of the portfolio and the stocks had doubled (GNVC and EMIS) and I did not like either. Anyway I blew out of the rest of GNVC and then it went up another 10% or so before collapsing. EMIS - not so lucky as I got caught with a tag-end of 10-15% of the shares when they finally collapsed. For awhile it looked stupid, but it turned out pretty well measured by avg realizations vs. his cost basis and the price at time of beginning to liquidate. The portfolio more than doubled. No one would have questioned me if I had just blown them out but so much better the way it turned out. You have to take what the markets give which is what some of these perma-bears just don't get.
Jon
Lot of biotech on list along with a bunch of China plays, in particular the lodging stocks which were and still are massively over valued. Some munis, short ETFs, and eastern Europeans with some distressed financials and education stocks. Also some shipping. Thanks for that.
Jon
One of the few big pharmas not in that seeking alpha article!
Jon
When I had my gallbladder out using keyhole surgery, I ended up with a doctor who was probably 10 years older than my ideal but decided his number of procedures (no actual numbers disclosed but this guy pioneered this type of surgery in Hong Kong a long ways back) and lack of complications (you don't want any nicks in this type of surgery from what I gathered) overweighed the age concern.
I got good, truthful answers on my questions.
Jon
Indevus bought someone a few years earlier than they got munched, also using CVRs as part of the currency. I will go back in my notes.
Jon
OT Rocky - Interesting. It showed on one of my weekend screens too. It is one of five high IV stocks with no earnings this cycle that popped up on my screens. Another interesting one to my thinking was VHC. I know nothing about CCME but these China names can go to zero overnight if fraud is suspected. Issue with VHC is that it is a super-margin stock for some reason (100% at E-trade which means 40-50% effective margin for naked straddles). I don't know if CCME is.
Jon
That’s exactly what I’m expecting Teva to tell the Judge. This ties right in with my conjecture in #msg-58703289 that Teva will go to great lengths to avert legal discovery.
Wouldn't that mean they might have to produce the full letter for discovery or would it be so severely redacted as not to give MNTA any insights?
Jon
Market having trouble digesting what this Minor Deficiency letter really is. MNTA soared and then cratered a bit (not big soaring and big cratering but some). Interesting. EDIT - found reference to similar letter from Sangstat in late 90s. Would be interesting to see if that drug got approved quickly or not.
Jon
My wife informs me our HK grocery bill is up 20 % recently. And rents are up double digits. Home prices 20+% last year.
Jon
That is interesting. We know that buyers of converts hedge by shorting the common. But I do not recall seeing it spelled out so clearly that the IB would do it for the buyer.
May already by posted but MNKD did it a while back too if my memory is right.
Jon
Zip,
Your post and one of mine and 2-3 others were listed over on Twitter for some reason. Interesting.
Jon
Nice trade!
Jon
I went in today on 100 june 16 calls for .78 and left at $1.45 five hours later.
It looks like you must have gotten in right before 11, or around 11:45. What tipped you off?
Jon
MNTA January option vols through roof. Many put prices have almost doubled while stock up. More volume in Jan and Feb puts than stock at one point.
Jon
I have been asked by PM to explain this and as I do not have PM capabilities, I thought it might be helpful to some (not many, but some) to explain better.
First statement simply meant that the implied volatility in MNTA options pricing had gone up quite a bit. Statement should have said all option volatilities through roof as I assume February probably rose more since it was past the "event horizon" of Teva decision (if Teva is to be believed).
The put option pricing started to explode higher around 12:33 as MNTA stock price dropped briefly (as Marsh was speaking I assume). And then even as stock recovered and shot upward, option pricing continued higher
In the 12:42 window, MNTA stock was trading right around $16 getting ready to explode higher (after having quickly dipped). That was the peak price for the Jan $14 puts (mentioned earlier by IJ and the focus of my previous selling with some selling today in that window at 0.70 but for very very small amounts). Working through an option calculator, the volatility in that particular option was 125% at that time. It had started the day in the low to mid 70% range (depending on bid or ask) and ended the day in the low 90% range.
I agree with Dew, people playing in these options are playing with fire as there is a high likelihood late January means post January 21 expiration. When I sold a very few puts (15) in that time-frame above, I did not know what was causing the spike. All I knew was the stock had started to tail off and was recovering still up nicely on day and that an option bidding 25 cents in the morning was being bid 50 cents. As the stock started to ramp, I thought that there had to be news/rumors in the market that Teva approval decision was imminent with longs taking that as good news and shorts as bad news and ramping both put prices and volatility higher. I came here and confirmed that thought with the hard news.
IJ - I can't remember when, but I have seen much harder volatility explosions in past. One example might be to go check MNKD volatilities on the date they announced they had re-filed Afrezza (caught market by surprise as it was a bit earlier than most thought and Jan 11 options came into approval window - of course recent delay took PDUFA out past Jan 11 options and you can see the process in reverse). But a vol ramp of 55% is not that big really. I am surprised it was that small mathematically.
The second part of the statement says that some put prices had doubled. The aforementioned Jan $14 puts had gone from 33 cent to 75 cents and were in the 60 cent range when I posted. The lower strikes had more than doubled.
At the time I did the calculation, there were about 8,000 put contracts traded in the Jan/Feb series, which equates to 800,000 shares. The stock had traded only 700,000 shares. A few minutes later this calculation yielded 9,000 contracts or 900,000 shares equivalent vs. 800,000 shares.
I just checked out vols across months for the $14 strike. The Jan vol is in the low 90s, the Feb vol is in the 124% range (to mid-point of bid/ask), and the March vol is in the 101% range. These are as I would expect with a small chance that January captures the event and the longer time-frame reducing IV as you get past the event. Vols for the Feb $14 puts were also in the low 70s at the open. I can't tell for the March series as the closing price yesterday looks illiquid and stale.
Interestingly the $19 calls have vols of 85% for January, 107% for February and 92% for March (to mid-points of big ranges in most cases). The put volatilities are modestly higher, usually indicative of a heavily-shorted hard-to-borrow stock. I hope this helps.
Jon
Put prices are sky high here. Especially Feb.
Jon
900,000 volume equiv in puts for Jan/Feb vs 800,000 volume. Put prices still flying. Wide market.
Jon
MNTA January option vols through roof. Many put prices have almost doubled while stock up. More volume in Jan and Feb puts than stock at one point.
Jon
I, a long-term bear, feel that the US economy is approaching glide path again and believe GDP will grow above 4% in 2011. Unemployment will drop toward 8% by late next year and Obama will be re-elected.
Jon
He sees the DOW at 1600 in the next two years
That should read S&P which is just over 30% from here.
Jon
This week, before interviewing the CEO of the biotechnology tools company LIFE, Jim Cramer suggested that one might be better off owning a company that makes all the necessary equipment rather than trying to pick the right biotech company.
Any thoughts on who those might be?
If nothing happens in another three months, I’ll reduce this number to $50M, and if nothing happens in another six months, I’ll say that the value is zero. JMHO, FWIW
Ahhhhhh, you are exactly (almost) matching the quarterly cash increases as long as sole generic status is maintained for Lovenox.
Jon
Mnta right now = vphm a few years ago before the acquisition. Vphm, once the generic threat came out, never really moved except up and down over the same ground, even with the cash build. That could be our fate UNTIL some new revenue producer actually happens. Mr. Market seems to doubt anything else is likely or imminent at this level.
Jon
At least the FDA doesn't just give in the way Congess does with all these tax cuts and new spending. We have a fiscal crisis AND we cut taxes AND increase spending?
Jon
That is quite a big spread for a quickie secondary. 5.5 percentish without doing hard math.
Jon
Usually the underwriter will sell 115 percent of the offering to accounts in the offering. It can then afford to buy in these shares at the fifer price and below and not exercise shoe. It also can trade around the stock. For a known hot stock it may only sell 100 percent and then short above and exercise shoe. More money is made by the stabilization agent in most offerings. The trading profits can eclipse the fees.
Jon
I am not sure lost "prospects" of 5 percent has the same zing as lost actual biz of 5 percent especially given the long timeframe and therefore low odds of approval. This is not actual biz being lost just an opportunity lost, which has a different standard, ESP since it could be grouped as part of potential new products bucket with all the other applications.
Jon
Devil's advocate - could also mean that MNTA has gotten word through grapevine that approval for Teva is imminent.
Jon
A bum gallbladder has the same impact with worse side effects! I only lost 15 percent though but have now gained 4 percent back.
Jon
I am used to the near the money vols being near 100 for some months. All are now in the 60s to 70s. That does mean the market is not looking for any major event risk vs past expectations.
Jon
Covered call premia do not properly compensate for gains foregone. This is coming from a guy who was short 2x the calls vs his long position last month although while also being short puts. Now I have my position with no options written.
Jon
I used to have a site to check average IVs over time. I cannot find any locales now with the data. Professional Bloomberg has it it but I don't have that. Ivolatility has it in the paid site.
Jon
I just did a quick scan of the vols in the options and other than a few way out of the money puts with massive bid/ask spreads, vols seem quite low for most strikes of puts and calls for all months. Anyone else noticing this? I definitely would agree with Dew now that selling the covered calls not worth the risk.
Jon
I am losing 500 shares net - selling 2000 at $15 (adjusted mid 16s) and buying at 1500 at 17 (net high 15s).
Jon
That hits one of my pet peeves - no one seems to care about matching pronouns to the precursor words. They/them are used more often than he/him/she/her after non-plural precursors and a corporation becomes them. Ugghh!
Jon
Asset managers tend to have their own analysts and these go by the moniker of buyside analysts. Go look at the Palo Alto Investor site for example and you will see several healthcare "analysts" on staff including the President, someone who I notice I knew in uni days but lost track of. FMR has numerous buyside analysts as do many hedge funds and other fund managers.
Jon
I have access to the CapitalIQ database - they have the following:
Institution 32 MM
Hedge Funds 8 MM
Corporations 5 MM
Insiders 2 MM
Total 45.5 MM - they net it down without explaining 1-2 MM missing shares.
Jon